Phase III clinical trials testing another PPARγ agonist, rosiglitazone, failed to show efficacy in patients with mild to moderate stages of Alzheimer's disease; however, the doses used in clinical trials were significantly lower than those shown to be beneficial in the rodent models (Gold et al., 2010). The gene discussed is PPARG; the disease is Alzheimer disease.